Upcoming Earnings Overview
The upcoming earnings report for ICLR is scheduled for Tuesday, April 28th, with a consensus estimate EPS of 3.21.
Live Analysis
ICON Public Limited Company (ICLR) is currently priced at $101.25, showing a decrease of $1.96 (-1.9%) from the previous close. The trading volume is at $489,181, representing a 25.5% increase compared to the average.
Earnings Overview
In the latest quarterly earnings report on Tuesday, March 31st, ICLR's consensus estimate EPS was 3.22. The consensus estimate revenue was reported at $2.00 billion.
Ratios
Key financial ratios for ICLR include a gross profit margin of 22.32%, operating profit margin of 12.67%, and a return on equity of 0.03. Notably, the company has a price-to-earnings ratio of 1437.41 and a price-to-sales ratio of 6.63.
Overall, ICLR's upcoming earnings report and current financial ratios indicate a mix of performance metrics that investors will be closely watching.
This article provides a snapshot of ICLR's financial status, offering insights into its recent performance and upcoming earnings expectations.
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It offers clinical development services, including early development, patient recruitment and retention, strategy and analytics, late phase research, data and technology solution, and consulting and analytics services. The company's clinical development services also comprise medical imaging, clinical research and laboratory services, project management, site monitoring and management services, data management, biostatistics and programming, medical writing and publishing, medical affair, endpoint adjudication/data monitoring committees, pharmacovigilance, interactive response technologies, clinical supplies management, strategic regulatory, medical communication, and consulting and advisory services. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company was incorporated in 1990 and is headquartered in Dublin, Ireland.